---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-022030"
form_type: "8-K"
ticker: "LCTX"
cik: "0000876343"
company_name: "Lineage Cell Therapeutics, Inc."
filed_at: "2023-06-21T23:59:59+00:00"
generated_at: "2026-06-13T20:25:48.122259+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Lineage Cell Therapeutics sets 2023 annual meeting for September 6; proposal deadline July 14

## Summary
- Annual Meeting scheduled for September 6, 2023.
- Shareholder proposals and nominations due by July 14, 2023.
- Rule 14a-8 proposals for proxy statement also due July 14.

## SEC filing metadata
- accession: 0001493152-23-022030
- form_type: 8-K
- ticker: LCTX
- cik: 0000876343
- company_name: Lineage Cell Therapeutics, Inc.
- filed_at: 2023-06-21T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/876343/000149315223022030/0001493152-23-022030-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/876343/000149315223022030/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-022030
- JSON: https://secwatch.observer/filing/0001493152-23-022030.json
- Plain text: https://secwatch.observer/filing/0001493152-23-022030.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.